Methods and compositions for poxvirus a35r protein
AssigneeEast Carolina University
InventorRachel Roper
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
Claims29
A method of modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
A method of treating or preventing an autoimmune disorder in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
A method of reducing the likelihood of transplant rejection in a transplant recipient, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
A method of enhancing an immune response to a poxvirus vaccine in a subject, comprising administering to the subject an effective amount of a poxvirus vaccine engineered to lack nucleic acid encoding an A35R protein and/or to lack A35R protein activity.
A method of enhancing an immune response in a subject to a heterologous antigen encoded by a poxvirus vector, comprising administering to the subject an effective amount of a poxvirus vector comprising nucleic acid encoding the antigen and wherein the poxvirus vector is engineered to lack nucleic acid encoding an A35R protein and/or to lack A35R protein activity.
A method of treating or preventing a detrimental immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus protein.
A method of treating or preventing a detrimental immune response in a subject wherein the detrimental immune response is caused by A35R protein activity, comprising administering to the subject an effective amount of a substance that inhibits A35R protein activity.
A method of enhancing an immunomodulating effect of a substance, comprising combining the substance with an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
A method of treating or preventing a poxvirus infection in a subject, comprising administering to the subject an effective amount of an inhibitor of A35R protein activity.
A method of diagnosing a poxvirus infection in a subject, comprising:
- a) contacting a sample from the subject with an antibody that specifically binds A35R protein under conditions whereby an antigen/antibody complex can form;
- and
- b) detecting formation of the antigen/antibody complex, thereby diagnosing poxvirus infection in a subject.
A method of diagnosing poxvirus infection in a subject, comprising:
- a) contacting a sample from the subject with an A35R protein or antigenic fragment thereof under conditions whereby an antigen/antibody complex can form;
- and
- b) detecting formation of the antigen/antibody complex, thereby diagnosing poxvirus infection in a subject.
A method of detecting poxvirus in a sample, comprising:
- a) contacting the sample with an antibody that specifically binds A35R protein under conditions whereby an antigen/antibody complex can form;
- and
- b) detecting formation of the antigen/antibody complex, thereby detecting poxvirus in the sample.
A method of detecting an antibody to poxvirus in a sample, comprising:
- a) contacting the sample with an A35R protein or antigenic fragment thereof under conditions whereby an antigen/antibody complex can form;
- and
- b) detecting formation of the antigen/antibody complex, thereby detecting an antibody to poxvirus in the sample.
A method of identifying nucleic acid comprising a nucleotide sequence encoding A35R protein in a sample, comprising:
- a) contacting the sample with an oligonucleotide comprising a nucleotide sequence that is complementary to the nucleotide sequence encoding A35R protein, under conditions whereby nucleic acid hybridization can occur;
- and
- b) detecting nucleic acid hybridization, thereby detecting nucleic acid comprising the nucleotide sequence encoding A35R protein in the sample.
A method of identifying nucleic acid comprising a nucleotide sequence encoding A35R protein in a sample, comprising:
- a) contacting the sample with a pair of oligonucleotide primers that are complementary to the nucleotide sequence encoding A35R protein, under conditions whereby nucleic acid amplification can occur;
- and
- b) detecting nucleic acid amplification, thereby detecting nucleic acid comprising the nucleotide sequence encoding A35R protein in the sample.
A method of treating cancer in a subject, comprising administering to the subject an effective amount of a poxvirus engineered to lack A35R protein activity.
The method of claim 20, wherein the poxvirus further comprises nucleic acid selected from the group consisting of:
- a) nucleic acid encoding a costimulatory molecule (e.g., B7.1, ICAM-1, LFA-3);
- b) nucleic acid encoding a tumor antigen;
- and
- c) nucleic acid encoding an immunomodulatory protein.
A composition comprising A35R protein and a pharmaceutically acceptable carrier.
A composition comprising a poxvirus engineered to lack A35R activity and a pharmaceutically acceptable carrier.
A method of modulating an immune response in a subject, comprising administering to the subject an effective amount of a nucleic acid encoding an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
A method of treating or preventing an autoimmune disorder in a subject, comprising administering to the subject an effective amount of a nucleic acid encoding an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
A method of reducing the likelihood of transplant rejection in a transplant recipient, comprising administering to the subject an effective amount of a nucleic acid encoding an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
A method of treating or preventing a detrimental immune response in a subject, comprising administering to the subject an effective amount of a nucleic acid encoding an A35R protein or active fragment thereof of vaccinia virus or other poxvirus protein.
A method of enhancing an immunomodulating effect of a substance, comprising combining the substance with a nucleic acid encoding an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.
A composition consisting essentially of a nucleotide sequence encoding a poxvirus A35R protein and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.